68Ga-FAPI-46

N/A

Report date: 2026/02/10 20:00:22

Base Information

Drug Name68Ga-FAPI-46
Drug Alias Name[68Ga]FAPI-4668Ga-FAPI-46
ClassificationRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agentSmall molecules > Heterocyclic drugs +[5] 
Mechanisms of ActionPositron-emission tomography enhancersFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsIntestinal FibrosisSolid tumoursPulmonary Fibrosis +[23] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeSweden +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKarolinska University Hospital
China Registration ClassN/A

Develop Information

Active CompaniesUniversität MünsterGE HealthCare Technologies IncRigshospitalet +[13] 
Inactive CompaniesVanderbilt University Medical Center
Active IndicationsIntestinal FibrosisPulmonary FibrosisRadiation Pneumonitis +[21] 
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A